Atopic Dermatitis | LEO Pharma | LP0162-1334
Pharmaceutical Company/Sponsor:
LEO Pharma
Code:
LP0162-1334
Title:
A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Trial to Evaluate the Efficacy, Safety, and Tolerability of Tralokinumab Monotherapy in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) Who Are Candidates for Systemic Therapy
Type:
Interventional
Phase:
3
Condition/Disease:
Atopic Dermatitis
Intervention(s)/Treatment(s):
Drug: Tralokinumab
Drug: Placebos
Status:
Active, Not Recruiting
Link for Additional Information:
